The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 11, 2016
Filed:
Dec. 16, 2013
Centro DE Ingeniería Genética Y Biotecnología, La Habana, CU;
Lisset Hermida Cruz, La Habana, CU;
Lázaro Gil González, Mayabeque, CU;
Alienys Izquierdo Oliva, Artemisa, CU;
Ernesto Marcos López, La Habana, CU;
Edith Suzarte Portal, La Habana, CU;
Gerardo Enrique Guillén Nieto, La Habana, CU;
María Guadalupe Guzmán Tirado, La Habana, CU;
Iris Valdés Prado, La Habana, CU;
Laura Lazo Vazquez, La Habana, CU;
Angelica de la Caridad Garcia Arechavaleta, La Habana, CU;
Mayling Alvarez Vera, La Habana, CU;
Jorge Castro Velazco, La Habana, CU;
Lázaro López Fernández, Artemisa, CU;
Rosa Liset Ramírez Bartutis, La Habana, CU;
Yusleidi de la Caridad Pérez Fuentes, La Habana, CU;
Olga Lidia Pérez Guevara, La Habana, CU;
Yaremy Romero Fernández, La Habana, CU;
CENTRO DE INGENIERÍA GENEÉTICA Y BIOTECHNOLOGÍA, La Habana, CU;
Abstract
Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.